HMO coverage of Rx-to-OTC switch products slipped to 27% in 1997 -- Novartis report.
This article was originally published in The Tan Sheet
Executive Summary
ANTIHISTAMINES, H2 ANTAGONISTS REIMBURSED BY OVER A THIRD OF HMOs in 1997, according to survey data reported in the recently- released "Novartis Pharmacy Benefits Report: 1998 Trends & Forecasts." With the exception of diabetic supplies and insulin, which topped all OTCs covered by health maintenance organizations last year, antihistamines and H2 blockers were listed by survey respondents as the OTC products covered by the most HMO plans. In 1997, antihistamines were reimbursed by 41% of HMOs, while H2 antagonists were covered by 36.4%, the report states.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC